DEVELOPMENT AND REGULATION OF MEDICINES: RUSSIAN AND INTERNATIONAL EXPERIENCE

  • 02.12.2023
  • 12:00–13:30
  • VDNH, 75 pavilion, Small hall 2
  • Broadcast
One of the key goals of the healthcare system worldwide is to provide citizens with high-quality, effective, and affordable drugs. To achieve this goal, the government needs the medical and pharmaceutical industries to be technologically independent, pharmaceutical production to be financially stable, and an effective state system to regulate the circulation of medicines, which will guarantee the quality and safety of medicines. It is also crucial to take into account the interests and needs of the business community that is directly involved in the production and sale of drugs. Above all else, these needs include transparent and business-oriented decisions in regulation, affordable investments in the industry by the government to develop and introduce innovative drugs, simplified administrative procedures for licensing and regulating drugs, the development of clear criteria to determine inventory shortages, measures to combat the counterfeiting of drugs, and a willingness among regulators to provide expanded preferences for full-cycle production. Another key factor in modernizing the drug regulation cycle is the analysis of best global practices, particularly in China and the Middle East, where the pharmaceutical industry is one of the developing national industries. How can we effectively accelerate the regulation of drug circulation in Russia? What additional support measures does the Russian pharmaceutical industry need? How can we properly use international experience to improve the processes of ensuring national drug safety? What forecasts exist for the overall state of the industry and the growth of the domestic pharmaceutical market over the next few years?

Трансляция